- PTC Therapeutics (NASDAQ:PTCT) +119.2% premarket after the Committee for Medicinal Products for Human Use of the European Medicines Agency issues a positive opinion on PTCT's application for a conditional marketing authorization of its Ataluren muscular dystrophy treatment.
- The news is a major upside surprise: Credit Suisse says a potential early EU approval for Ataluren has not been priced in to shares.
- Others involved in Duchenne muscular dystrophy treatments also trade higher premarket: RNA +16%, SRPT +3%.